Working Paper Review Version 1 This version is not peer-reviewed

Antivirals against the Chikungunya Virus

Version 1 : Received: 9 June 2021 / Approved: 10 June 2021 / Online: 10 June 2021 (09:15:45 CEST)

How to cite: Battisti, V.; Urban, E.; Langer, T. Antivirals against the Chikungunya Virus. Preprints 2021, 2021060284 Battisti, V.; Urban, E.; Langer, T. Antivirals against the Chikungunya Virus. Preprints 2021, 2021060284

Abstract

Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that has re-emerged in recent decades, causing large-scale epidemics in many parts of the world. CHIKV infection leads to a febrile disease known as chikungunya fever (CHIKF), which is characterised by severe joint pain and myalgia. As many patients develop a painful chronic stage and neither antiviral drugs nor vaccines are available, the development of a potent CHIKV inhibiting drug is crucial for CHIKF treatment. A comprehensive summary of current antiviral research and development of small-molecule inhibitor against CHIKV is presented in this review. We highlight different approaches used for the identification of such compounds and further discuss the identification and application of promising viral and host targets.

Subject Areas

Chikungunya virus; alphavirus; antiviral therapy; direct-acting antivirals; host-directed antivirals; in silico screening; in vivo validation; antiviral drug development

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.